Explainer: What's next for Purdue Pharma after $6 billion opioid settlement?


March 8 (Reuters) - Members of the Sackler family that own Purdue Pharma struck a new settlement last week with a group of eight states and the District of Columbia to resolve widespread litigation accusing the OxyContin maker of fueling the U.S. opioid epidemic. 

The following details next steps for Purdue and potential hurdles as it moves closer to exiting bankruptcy.

What is in the revised deal?